Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

OBJECTIVE: This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis in addition to standard‐of‐care (SOC) treatment with glucocorticoids with cyclophosphamide or rituximab...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkel, Peter A., Niles, John, Jimenez, Richard, Spiera, Robert F., Rovin, Brad H., Bomback, Andrew, Pagnoux, Christian, Potarca, Antonia, Schall, Thomas J., Bekker, Pirow
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672305/
https://www.ncbi.nlm.nih.gov/pubmed/33128347
http://dx.doi.org/10.1002/acr2.11185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672305/
https://www.ncbi.nlm.nih.gov/pubmed/33128347
http://dx.doi.org/10.1002/acr2.11185

Ejemplares similares